Skip to main content
. 2020 May 29;6(8):1–10. doi: 10.1001/jamaoncol.2020.2020

Figure 2. Treatment Response Among 67 Patients With ERBB2-Negative and ERBB2-Positive Advanced Gastroesophageal Cancer Treated With FOLFIRINOX.

Figure 2.

A, Best percentage change in target lesions from baseline in patients with ERBB2-negative disease. Each bar represents a patient. Dotted lines indicate changes in target lesion size of −30% and +20%. B, Time to and duration of response in patients with ERBB2-negative disease. C, Best percentage change in target lesions from baseline in patients with ERBB2-positive disease. D, Time to and duration of response in patients with ERBB2-positive disease.

CR indicates complete response; FOLFIRINOX, leucovorin, fluorouracil, irinotecan, and oxaliplatin; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.